In particular, it is considered that the concentration of the neutralizing antibodies, which are expected to block a step of the viral replication cycle by binding to the surface of viral particles, thereby reducing their infectivity, determines the efficacy of CP and hyperimmunoglobulin therapies for patients with COVID-19 [10,11]. Here, CP is linked to COVID-19.